CTIS2023-503620-60-00进行中（未招募）1 期
64407564MMY1004
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 182
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple MyelomaMultiple myelomaCTIS2023-503468-17-00Janssen - Cilag International290
进行中（未招募）
1 期
A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination with Checkpoint Inhibition for the Treatment of Participants with Relapsed or Refractory Multiple MyelomaCTIS2022-502681-24-00Janssen - Cilag International66
招募中
1 期
A study in healthy subjects investigating the safety, tolerability and concentrations of FE 999301 after single and multiple dosesInflammatory Gastrointestinal DiseaseMedDRA version: 20.0Level: HLGTClassification code: 10017969Term: Gastrointestinal inflammatory conditions Class: 10017947CTIS2023-507882-24-00Ferring Pharmaceuticals A/S48
招募中
1 期
An exploratory study to investigate the effect of FE 999302 when given during different time periods to women undergoing controlled ovarian stimulation with follitropin deltaInfertility in women undergoing assisted reproductive technologies (ART)CTIS2023-508149-42-00Ferring Pharmaceuticals A/S200
进行中（未招募）
1 期
A Study to Learn How Different Amounts and Forms of the Study Intervention Called PF-07899895 are Tolerated and Act in the Body of Healthy Adultslcerative ColitisMedDRA version: 20.0Level: PTClassification code: 10009900Term: Colitis ulcerative Class: 100000004856CTIS2023-507354-32-00Pfizer Inc.45